Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.

International journal of cancer - 10 Jan 2004

Blumenthal Rosalyn D, Leone Evelyn, Goldenberg David M, Rodriguez Marisol, Modrak David

Abstract excerpt

Several reports have appeared on the use of combined radioimmunotherapy (RAIT) and chemotherapy. The choice of drug to use with RAIT and how to space the two treatments has not been completely addressed. Because every patient's cancer presents with a specific molecular phenotype, we hypothesized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Combined Modality Therapy
Share to Doxorubicin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Genetic Therapy

Share to Paclitaxel

Share to Tetrazolium Salts

Share to Thiazoles

Source

Identifiers

PMID: 14639618
DOI: 10.1002/ijc.11534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-14639618-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: effects of p53 expression.PMID 14639618Read ↗

Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.Semantic proximity Read ↗

Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53.Semantic proximity Read ↗

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood CancersSemantic proximity Read ↗

Wortmannin sensitizes human glioblastoma cell lines carrying mutant and wild type TP53 gene to radiation.Semantic proximity Read ↗

Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.Semantic proximity Read ↗

Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of p53 mutant cell lines.Semantic proximity Read ↗

Synergistic anti-tumor effects of nitroreductase mutants and p53.Semantic proximity Read ↗

TP53 Mutational Status and ROS Effect the Expression of the Survivin-Associated Radio-Adaptive Response.Semantic proximity Read ↗

Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells.Semantic proximity Read ↗

Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.Semantic proximity Read ↗

SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells.Semantic proximity Read ↗

p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.